AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Thursday 22 October 2026
News from the 24 hours to Thursday morning, 22 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage focused on positive Phase III Tezspire results in eosinophilic esophagitis, an FDA approval for Ultomiris in a rare kidney disease, and a new AI clinical trials partnership with Oracle. Analyst Buy ratings added support, while a drug withdrawal and an earlier trial miss were minor negatives.
What drove it
- Phase III Tezspire results
- Ultomiris FDA approval
- Oracle AI partnership
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 16 Oct | +5.7 | 38 |
| Sat 17 Oct | +6.3 | 32 |
| Sun 18 Oct | +5.7 | 6 |
| Mon 19 Oct | +4.0 | 3 |
| Tue 20 Oct | +5.5 | 24 |
| Wed 21 Oct | +8.7 | 38 |
| Thu 22 Oct | +8.3 | 28 |
| Fri 23 Oct | +8.3 | 32 |
| Sat 24 Oct | +9.2 | 8 |
| Sun 25 Oct | +10.0 | 16 |
| Mon 26 Oct | +10.0 | 33 |
10 stories · 28 headlines · strongest first
Pharma and healthcare on 22 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca and Oracle start a worldwide collaboration on AI +5.88 headlines today · 38 in all, since 20 October · Outlets report the AstraZeneca-Oracle AI partnership for clinical trials. | ||
| +7.0 | Oracle AI collaboration to speed drug development. | |
| +6.7 | Oracle collaboration on smarter clinical trials. | |
| +6.7 | AI partnership with Oracle for trial recruitment. | |
| +6.7 | Oracle AI team-up to speed trials. | |
| +6.7 | Oracle AI clinical trials partnership. | |
| +6.7 | AI deal to accelerate trials and diagnosis. | |
| +6.7 | Oracle partnership to optimise clinical trials. | |
| +6.3 | AI trial recruitment collaboration with Oracle. | |
| Tezspire shows positive Phase 3 results in eosinophilic esophagitis +10.05 headlines today · 20 in all, since 21 October · Amgen and AstraZeneca reported positive Phase III Tezspire EoE results. | ||
| +10.0 | Phase III trial in EoE returned positive outcomes. | |
| +10.0 | Positive Phase III Tezspire results in EoE. | |
| +10.0 | Phase 3 Tezspire success lifts momentum. | |
| +9.2 | Phase III Tezspire EoE data reported. | |
| +8.3 | Favourable EoE data from Phase III viewed as possible benefit. | |
| FDA gives Ultomiris accelerated approval for IgA nephropathy +9.35 headlines today · 18 in all · The FDA has approved AstraZeneca's Ultomiris for use in adults who have a rare kidney condition. | ||
| +10.0 | FDA approval for adults with an uncommon kidney disease. | |
| +10.0 | Ultomiris gets FDA approval to treat a rare kidney disease. | |
| +9.5 | Drug for a rare kidney disease receives FDA approval. | |
| +9.5 | FDA gives the go-ahead to a drug for a rare kidney disease. | |
| +9.2 | Ultomiris approval to reduce proteinuria. | |
| Brokers keep ratings on AstraZeneca +6.43 headlines today · JP Morgan keeps Buy and Jefferies keeps a 17,500p target. | ||
| +6.7 | JP Morgan recommends buying the shares. | |
| +6.7 | JP Morgan maintains Buy rating. | |
| +5.8 | Jefferies keeps high price target. | |
| AstraZeneca valuation and peer comparison pieces +2.12 headlines today · Pieces compare AstraZeneca with AbbVie and ask if it is cheap. | ||
| +2.5 | Valuation discussion, mildly positive framing. | |
| +1.7 | Earnings growth comparison with AbbVie, roughly neutral. | |
| AstraZeneca to show ESMO 2026 data from four trials in Phase III +6.41 headline today · 7 in all, since 20 October · At ESMO, AstraZeneca will reveal survival results drawn from four cancer trials in Phase III. | ||
| +6.7 | Pivotal survival results from a quartet of Phase III studies to be presented. | |
| AstraZeneca signs $1.46bn AI deal +6.31 headline today · 4 in all, since 20 October · AstraZeneca agreed an AI deal worth USD 40 million. | ||
| +5.8 | Agrees an AI deal valued at USD 40 million. | |
| AstraZeneca inaugurates new corporate premises in Mumbai +5.01 headline today · 10 in all, since 17 October · AstraZeneca opened a 25,600 sq ft Mumbai office. | ||
| +3.3 | New Mumbai office opening, minor expansion. | |
| AstraZeneca withdraws labour ward drug −3.31 headline today · AstraZeneca's withdrawal of its labour ward drug is attributed to the product not being commercially viable. | ||
| −3.3 | Drug withdrawn because it is not commercially viable. | |
| AstraZeneca Wainua trial miss and dividend −0.81 headline today · Kalkine asks whether AZ can shrug off the Wainua miss. | ||
| −0.8 | Trial miss weighed against raised interim dividend. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.